Dutch Cancer Society
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
2002 · Marc J. van de Vijver, Yudong D. He, et al. · New England Journal of Medicine
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
2015 · Antoni Ribas, Igor Puzanov, et al. · The Lancet Oncology
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
2015 · Georgina V. Long, Daniil Stroyakovskiy, et al. · The Lancet